Tempus AI Delivers Big Q4 Revenue Jump but Falls Short on Profitability
Tempus AI, a leading player in AI-powered diagnostics and data services, announced its fourth-quarter results amid a market environment hungry for growth stories but wary of margins. The company disclosed $367 million in Q4 revenue, up 83% from the year-ago period, signaling robust demand for its diagnostic and data-enabled platforms. Yet investors are focusing on the profitability trajectory after a January pre-announcement left a profitability path murky.
Key Numbers: Revenue Soars, Margins lag
- Q4 revenue: $367 million, up 83% year over year.
- Diagnostics revenue: $266 million in Q4, a jump of 121% from a year earlier.
- Data and apps revenue: $100 million in Q4, up 25% year over year.
- Non-GAAP EPS (Q4): -$0.04, better than the -$0.05 consensus estimate.
- Adjusted EBITDA (Q4): $12.9 million, up from $1.5 million in the prior quarter.
- Adjusted EBITDA (full-year 2025): -$7.4 million, below management’s prior goal of slight profitability.
Despite the strong top line, the company cautioned that profitability remains a work in progress. The Q4 print arrived with a larger emphasis on profitability hurdles tied to stock-based compensation and other non-cash items that weighed on GAAP figures. As a result, investors reacted by trimming holdings in after-hours trading, with shares hovering around the mid-$50s after a prior close near $59.
Guidance for 2026: A Growth Path With a Profitability Milestone
Tempus AI laid out a 2026 plan intended to translate growth into meaningful earnings. The company guided toward approximately $1.59 billion in revenue for 2026, implying roughly 25% annual growth from 2025 levels. On the profitability front, management set an Adjusted EBITDA target of about $65 million for 2026, signaling a recovery in margins even as the business continues to scale.
- 2026 revenue guide: ~ $1.59 billion (about 25% growth).
- 2026 Adjusted EBITDA guide: ~$65 million.
- 2025 full-year results: adjusted EBITDA negative, erasing earlier optimism about a return to profitability.
The company’s executives stressed that the 2026 plan is contingent on sustaining demand in diagnostics while expanding data and applications adoption. They argued that the mix shift toward higher-margin services could gradually improve margins, even as the company continues to reinvest in product development and go-to-market capacity.
Markets React: What the Street is Watching
Investors have been weighing whether Tempus AI can keep its rapid revenue growth while turning a profit on a full-year basis. The stock’s reaction to the latest results reflected a cautious mood, with shares retreating in after-hours trading and adding to a recent volatility pattern common to high-growth AI names after quarterly updates.
Analysts point to a familiar tension in growth benchmarks: topline acceleration versus engine efficiency. If Tempus AI can achieve its $65 million 2026 Adjusted EBITDA target while continuing double-digit revenue growth, the stock could re-rate on a better-margin narrative. If not, the focus may shift toward the durability of its revenue mix and the timeline for sustainable profitability.
Management Commentary: What The Company Is Saying
Tempus AI executives underscored the long game in a post-release notes and conference call. In a statement reviewed by reporters, the company’s CFO highlighted that the 2026 targets reflect an inflection point as the platform expands clinically and commercially. A Tempus AI spokesperson added that the trajectory hinges on patient outcomes, hospital adoption, and the continued monetization of data and apps alongside diagnostics.
“While we delivered strong top-line growth, we recognize that profitability remains a priority for our shareholders,” a Tempus AI official said. “The 2026 plan is designed to convert growth into durable earnings as we scale the platform across more markets.”
Another executive emphasized operational efficiency gains and a leaner cost structure in later-stage quarters, noting that the company would manage investments to align with cash-generation timelines. The tone suggests management intends to balance aggressive product development with disciplined expense control as the business moves toward its profitability milestones.
Industry Context: AI in Diagnostics and Data Platforms
The Tempus AI results arrive as the AI-focused health tech sector grapples with the pace of adoption, regulatory considerations, and the path to profitability. Diagnostics platforms have benefited from increasing demand for rapid, data-driven decision support, while data and apps revenue reflects a broader push to monetize analytics and application ecosystems beyond core testing services.
Analysts note that the company’s revenue growth is a compelling signal of market traction, but the durability of that growth will depend on customer stickiness, integration with existing clinical workflows, and competitive dynamics in AI-assisted healthcare. In this environment, tempus posts revenue growth appears to be a key narrative, even as investors scrutinize margins and cash-burn trajectories.
What Investors Should Watch Next
- Margin trajectory: Can 2026 EBITDA approach the $65 million target while maintaining revenue growth?
- Demand durability: Will diagnostics and data/apps continue to outpace market expectations into 2026?
- Cash flow evolution: How far will stock-based compensation and non-cash charges weigh on GAAP profitability?
- Competitive landscape: How will Tempus AI differentiate itself amid rising AI-in-healthcare competitors?
For investors, tempus posts revenue growth remains a central talking point, but the ultimate test lies in whether margin discipline can catch up with top-line momentum. As the AI industrial complex benchmarks its progress, Tempus AI’s 2026 road map will be closely watched by bulls and skeptics alike.
Bottom Line: Growth Is Clear, Profitability Is The Focus
The latest quarter confirms Tempus AI can deliver significant revenue growth and advancing profitability metrics in the near term. The 83% Q4 revenue surge reinforces tempus posts revenue growth as a strong talking point for investors seeking long-term upside. Yet the company’s full-year profitability target remains a work in progress, requiring continued execution on cost controls and margin expansion as it scales. With 2026 revenue and EBITDA targets laid out, market participants will be watching closely to see if Tempus AI can translate growth into durable earnings power in an increasingly competitive AI healthcare landscape.
Discussion